Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Choosing a retirement plan over a 401k can be beneficial in specific situations. Discover when to make this important choice.
25,535 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
When big tech teams up, investors take notice. This article digs into why AMD stock jumped today, what the Microsoft ...
Two heavyweight banks reported solid Q4 2025 results, but investors remain focused on dividends, buybacks and how eac...
Ford's fourth quarter shocked many investors: a massive net loss despite solid revenue. This article peels back the d...
Federal prosecutors accuse a Goliath Ventures executive of running a crypto investment scheme that defrauded roughly ...
When a defense stock pops, investors want the quick answer: is this a one-off move or a real trend? This article brea...
Two leading prediction-market platforms are pursuing high-value fundraising as U.S. lawmakers eye tighter rules. Iran...
The Invesco S&P 500 Momentum ETF (SPMO) is again outperforming SPY on a trailing basis while showing resilience durin...
As kimball (ke) 2026 earnings unfold, investors care most about revenue growth, margin stability, and cash flow. This...
Rocket Lab is expanding by purchasing a competing space systems group for up to $60 million. This article breaks down...
A notable fund exited a sizable stake in Huron Consulting Group, locking in gains and signaling a disciplined approac...
In 2022, the 3x levered ETF SOXL plunged about 90%, even as the broader semiconductor group endured a mid-cycle decli...